IceCure Medical Ltd (ICCM)
| Market Cap | 19.48M -70.8% |
| Revenue (ttm) | 3.38M +2.7% |
| Net Income | -15.06M |
| EPS | -0.24 |
| Shares Out | 81.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 522,235 |
| Open | 0.2510 |
| Previous Close | 0.2500 |
| Day's Range | 0.2375 - 0.2599 |
| 52-Week Range | 0.2375 - 1.4000 |
| Beta | 1.63 |
| Analysts | Strong Buy |
| Price Target | 2.50 (+941.67%) |
| Earnings Date | May 27, 2026 |
About ICCM
IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncolo... [Read more]
Financial Performance
In 2025, IceCure Medical's revenue was $3.38 million, an increase of 2.67% compared to the previous year's $3.29 million. Losses were -$15.06 million, -1.70% less than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for ICCM stock is "Strong Buy" and the 12-month stock price target is $2.5.
News
IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026
CAESAREA, Israel, May 6, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys...
IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market
As the only FDA cleared minimally invasive treatment option for low-risk breast cancer, ProSense® is aligned with the trend toward de-escalation of breast cancer treatment—a key theme at this year's m...
IceCure Medical initiated with a Buy at Alliance Global
Alliance Global analyst Scott Henry initiated coverage of IceCure Medical (ICCM) with a Buy rating and $1 price target IceCure is an Israel-based medical technology company developing and commercializ...
IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025
The Company's participation at the Society of Breast Imaging Symposium and other upcoming medical conferences are timely as commercial momentum accelerates Cryoablation cost analysis study from Massac...
IceCure Medical files to sell 16M ordinary share for holders
16:33 EDT IceCure Medical (ICCM) files to sell 16M ordinary share for holders
IceCure Medical announces $4M registered direct offering
IceCure Medical (ICCM) announced that it has entered into securities purchase agreements with healthcare focused institutional investors for the purchase and sale of 8M ordinary shares at a purchase p...
IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement
CAESAREA, Israel, March 26, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destr...
IceCure Medical reports results from clinical trial of ProSense for SRMs
IceCure Medical (ICCM) announced positive top-line results from its ICESECRET clinical trial of ProSense for the treatment of small renal masses, or SRMs, in kidney cancer patients. A total of
IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates
At a median follow-up of four years, 89.4% recurrence-free rate in patients with tumors ≤3 cm and no prior kidney cancer; 83.9% recurrence-free rate for general study population Full analysis of resul...
IceCure Medical appoints Meir Peleg as CFO
IceCure Medical (ICCM) appointed Meir Peleg as its CFO, effective May 17. Meir Peleg combines a software engineering background with over 20 years of financial leadership, having previously served as
IceCure Appoints Meir Peleg as Chief Financial Officer
Meir Peleg brings over 20 years of financial leadership and experience including with Nasdaq listed companies IceCure intends to appoint Dr. Richard Fine as Medical Director CAESAREA, Israel, March 24...
IceCure Medical Earnings Call Transcript: Q4 2025
Record 2025 revenue of $3.4M was driven by FDA clearance and new guidelines for ProSense, fueling strong U.S. and global adoption. Expansion into Canada and Japan, a 30-site post-marketing study, and reimbursement improvements are expected to accelerate growth.
IceCure Medical reports FY25 EPS 24c vs 30c last year
Reports FY25 revenue $3.379M vs $3.291M last year. “2025 was a pivotal year for IceCure. Following the FDA’s clearance for cryoablation of low-risk breast cancer in October, we had record
IceCure Reports 2025 Full Year Financial & Operational Results
Record 4th quarter and full year sales of $1.3 million and $3.4 million, respectively Strong commercial momentum for ProSense® in the U.S. and globally following FDA clearance in low-risk breast cance...
IceCure Medical receives FDA approval for ProSense study
IceCure Medical (ICCM) announced that the FDA has approved the study design for the “ChoICE Trial Post-Market Study,” the Company’s post-marketing study for ProSense in the treatment of low-risk breas...
U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer
IceCure is engaged with leading medical institutions throughout the U.S. looking to participate in the post-market study with the FDA-cleared ProSense® Clinical study sites may offer ProSense® cryoabl...
IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026
CAESAREA, Israel, March 10, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destr...
American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer
IceCure's ICE3 study and the FDA Advisory Panel's favorable vote on ProSense® cryoablation's benefit-risk profile for low-risk breast cancer played a key role in the ASBrS 2026 Resource Guide update N...
IceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense® Cryoablation Safe and Effective in Treatment of Breast Fibroadenomas
Treatment with ProSense® resulted in 92.9% volume reduction of fibroadenoma one-year post-cryoablation Findings may impact treatment guidelines issued by medical societies for large non-cancerous brea...
IceCure Medical completes 5-year follow up study in kidney cancer cryoablation
IceCure Medical (ICCM) announced the completion of its last patients’ five-year follow up evaluation in its ICESECRET clinical trial of ProSense for the treatment of small renal masses in kidney
IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026
Previously released interim data from 111 patients demonstrated ProSense® is safe and effective in destruction of kidney tumors with 88.7% recurrence-free rate Incidence of kidney cancer is growing wo...
IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense®, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation
First procedures to be performed in the coming weeks at Alabama's largest non-governmental healthcare system Purchase funded by the Thomas Foundation following FDA marketing authorization of ProSense®...
IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense®
ProSense® system recently received FDA marketing authorization for the treatment of low-risk breast cancer Cryoablation for breast cancer is now included in proposed medical society guidelines for the...
IceCure Medical announces departure of CFO Ronen Tsimerman
IceCure Medical (ICCM) announced that after nearly a decade of service with IceCure, CFO Ronen Tsimerman has informed the company of his decision to leave the company to pursue new
IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved
Ronen Tsimerman will continue as CFO until successor is appointed CAESAREA, Israel, Feb. 9, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a ...